These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23851053)

  • 21. Gender-specific neuroimmunoendocrine aging in a triple-transgenic 3xTg-AD mouse model for Alzheimer's disease and its relation with longevity.
    Giménez-Llort L; Arranz L; Maté I; De la Fuente M
    Neuroimmunomodulation; 2008; 15(4-6):331-43. PubMed ID: 19047809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selecting a mouse model of Alzheimer's disease.
    Chin J
    Methods Mol Biol; 2011; 670():169-89. PubMed ID: 20967591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cognitive-Enhancing Effects of a Polyphenols-Rich Extract from Fruits without Changes in Neuropathology in an Animal Model of Alzheimer's Disease.
    Dal-Pan A; Dudonné S; Bourassa P; Bourdoulous M; Tremblay C; Desjardins Y; Calon F;
    J Alzheimers Dis; 2017; 55(1):115-135. PubMed ID: 27662290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine.
    Nagakura A; Shitaka Y; Yarimizu J; Matsuoka N
    Eur J Pharmacol; 2013 Mar; 703(1-3):53-61. PubMed ID: 23276665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease.
    Blain JF; Bursavich MG; Freeman EA; Hrdlicka LA; Hodgdon HE; Chen T; Costa DE; Harrison BA; Kapadnis S; Murphy DA; Nolan S; Tu Z; Tang C; Burnett DA; Patzke H; Koenig G
    Alzheimers Res Ther; 2016 Aug; 8(1):34. PubMed ID: 27572246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alzheimer's disease: transgenic mouse models and drug assessment.
    Yu P; Oberto G
    Pharmacol Res; 2000 Aug; 42(2):107-14. PubMed ID: 10887038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases.
    Hölscher C
    Sheng Li Xue Bao; 2014 Oct; 66(5):497-510. PubMed ID: 25331995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cognitive recovery and restoration of cell proliferation in the dentate gyrus in the 5XFAD transgenic mice model of Alzheimer's disease following 2-hydroxy-DHA treatment.
    Fiol-deRoque MA; Gutierrez-Lanza R; Terés S; Torres M; Barceló P; Rial RV; Verkhratsky A; Escribá PV; Busquets X; Rodríguez JJ
    Biogerontology; 2013 Dec; 14(6):763-75. PubMed ID: 24114505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repurposing Licensed Drugs for Use Against Alzheimer's Disease.
    Norins LC
    J Alzheimers Dis; 2021; 81(3):921-932. PubMed ID: 33843684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug Repositioning for Alzheimer's Disease: Finding Hidden Clues in Old Drugs.
    Ihara M; Saito S
    J Alzheimers Dis; 2020; 74(4):1013-1028. PubMed ID: 32144994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the effects of selenomethionine and selenium-enriched yeast in the triple-transgenic mouse model of Alzheimer's disease.
    Zhang ZH; Wu QY; Chen C; Zheng R; Chen Y; Ni JZ; Song GL
    Food Funct; 2018 Jul; 9(7):3965-3973. PubMed ID: 29974078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of the APP23 transgenic mouse model of Alzheimer's disease through evaluation of risperidone treatment on aggressive behaviour.
    Vloeberghs E; Coen K; Van Dam D; De Deyn PP
    Arzneimittelforschung; 2008; 58(6):265-8. PubMed ID: 18677967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topical Discoveries on Multi-Target Approach to Manage Alzheimer's Disease.
    Batool A; Kamal MA; Rizvi SMD; Rashid S
    Curr Drug Metab; 2018; 19(8):704-713. PubMed ID: 29512457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alzheimer's disease: old problem, new views from transgenic and viral models.
    Jaworski T; Dewachter I; Seymour CM; Borghgraef P; Devijver H; Kügler S; Van Leuven F
    Biochim Biophys Acta; 2010 Oct; 1802(10):808-18. PubMed ID: 20332023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease.
    Terwel D; Dewachter I; Van Leuven F
    Neuromolecular Med; 2002; 2(2):151-65. PubMed ID: 12428809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease.
    Kazim SF; Blanchard J; Dai CL; Tung YC; LaFerla FM; Iqbal IG; Iqbal K
    Neurobiol Dis; 2014 Nov; 71():110-30. PubMed ID: 25046994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of Amyloid-β and Tau Pathologies, Associated Neurodegeneration, and Cognitive Deficit by Early Treatment with a Neurotrophic Compound.
    Baazaoui N; Iqbal K
    J Alzheimers Dis; 2017; 58(1):215-230. PubMed ID: 28387677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The flavonoid quercetin ameliorates Alzheimer's disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer's disease model mice.
    Sabogal-Guáqueta AM; Muñoz-Manco JI; Ramírez-Pineda JR; Lamprea-Rodriguez M; Osorio E; Cardona-Gómez GP
    Neuropharmacology; 2015 Jun; 93():134-45. PubMed ID: 25666032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.